ELLKAY Solutions
ELLKAY’s latest innovation, the LKOrbit platform, addresses the pressing challenges faced by laboratories today. Built upon two decades of industry expertise, LKOrbit offers tailored solutions to combat issues like supply chain disruptions, declining reimbursement rates, data accuracy concerns, and staffing shortages. With its comprehensive features, LKOrbit aims to streamline operations, optimize reimbursements, and drive lab…
Latest
Articles
LKOpera: The Solution for Interoperability Among Health IT Systems
In today’s tech-driven healthcare landscape, mastering interoperability is key to driving growth and innovation. LKOpera revolutionizes data connectivity, breaking down silos between health IT systems and expediting integrations across various applications. With its cloud-based platform, LKOpera streamlines data sharing, accelerates implementations, and provides full control over data access, all while simplifying complex connections. Experience the…
Articles
LKOrbit: Maximize Lab Reimbursements with ELLKAY
Ellkay introduces its laboratory connectivity platform, LKOrbit , emphasizing its potential to revolutionize order processing and reimbursements in healthcare. By addressing challenges such as data accuracy and interoperability, the LKOrbit offers a comprehensive solution for labs to streamline operations and maximize revenue. With features like electronic order transmission and automated data retrieval, LKOrbit aims to…
Articles
LKArchive: Hospitals and Health Systems Decommission Legacy Applications
A smart data strategy is crucial for efficient patient care delivery. ELLKAY’s expertise in data migration, archiving, and interoperability offers healthcare providers a comprehensive solution to cut costs, bolster data security, and seamlessly integrate disparate systems. With LKArchive, organizations can consolidate data, retire legacy applications, and empower healthcare teams with instant access to complete patient…
Articles
LKClinicalDataExchange: Experience the Power of True Interoperability
Unlocking the potential of seamless clinical data exchange, ELLKAY introduces its groundbreaking solution, LKClinicalDataExchange. Addressing the pressing need for true interoperability in healthcare, this platform empowers health plans to comply with CMS mandates, support value-based care, and provide patients with access to their health data. Leveraging ELLKAY’s expertise in data connectivity, migration, and integration, LKClinicalDataExchange…
Latest
Analyzing the Suppressive TME in In Vitro Based Assays
In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…
Targeting T Cells Within the Cancer Immunity Cycle
As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…
Inside Oncology Drug Development: Overcoming Resistance with Science
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…
